Focus: Roche is a 128-year-old Swiss pharma giant with 100,000 employees, headquartered in Stavanger, Norway, operating across oncology, neuroscience, immunology, and diagnostics. The company maintains a diversified portfolio of small molecules and biologics with significant market penetration.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Hot — 1729 jobs added in 30d
Net +675 (1729 new, 1054 removed). Aggressive expansion phase.
3 recent layoff filings (12 mo) — 346 affected
Source: state DOL filings via Big Local News
Roche offers blue-chip stability and global reach, but recent layoffs and revenue concentration warrant careful evaluation of team stability and role longevity.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Largest single revenue driver at 23% of portfolio but facing patent expiration with no disclosed LOE date.
Help build intelligence for Roche
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Roche's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Second-largest revenue contributor with strong oncology franchise and extended patent protection through 2035.
Established biologic franchise with sustained peak-phase revenue and durable market position.
High-growth neuroscience asset with long patent tail (2041) and differentiated mechanism in rare disease segment.
Niche oncology product facing patent cliff in 2028, representing $103M in near-term revenue vulnerability.
Pioneering mAb with extensive off-label use but facing biosimilar erosion and no disclosed patent expiration.
Rare disease antibody therapeutic with niche but stable market positioning.
Checkpoint inhibitor in competitive oncology space with sustained but modest peak-phase revenue.
Precision oncology asset with imminent patent cliff (October 2026), first major loss-of-exclusivity event on horizon.
95 discontinued, 23 duplicate formulations not shown
+17 more products with revenue data
Roche obesity drug helps patients shed 22.7% of weight in mid-stage trial - Reuters
Roche obesity drug helps patients shed 22.7% of weight in mid-stage trial Reuters
Roche's Enicepatide: A Game-Changer in the Obesity Drug Race - Devdiscourse
Roche's Enicepatide: A Game-Changer in the Obesity Drug Race Devdiscourse
Roche Chairman Severin Schwan Blasts U.S. Tariff Tactics as “Cold-Blooded Blackmail,” - Tekedia
Roche Chairman Severin Schwan Blasts U.S. Tariff Tactics as “Cold-Blooded Blackmail,” Tekedia
Roche chair compares US tariff policy to ‘blackmail’ - SWI swissinfo.ch
Roche chair compares US tariff policy to ‘blackmail’ SWI swissinfo.ch
Roche chair compares US tariff policy to ‘blackmail’ - SWI swissinfo.ch
Roche chair compares US tariff policy to ‘blackmail’ SWI swissinfo.ch
Roche Chairman Accuses US Government of Drug Price ‘Blackmail’ - Bloomberg.com
Roche Chairman Accuses US Government of Drug Price ‘Blackmail’ Bloomberg.com
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via
Recent peer-reviewed publications with author affiliations at this company
+13 more products
+2 more
Concentrated layoffs at one major R&D hub (South San Francisco) suggest targeted portfolio or function restructuring rather than across-the-board headcount cuts, warranting location-specific diligence.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo